Tumefactive hemosiderotic fibrohistiocytic shrapnel stromal reaction of the hand

2019 ◽  
Vol 47 (2) ◽  
pp. 189-191
Author(s):  
Badr AbdullGaffar ◽  
Sheela Prince
Keyword(s):  
Stromal Reaction

Cervical cancer: The diagnostic value of rectosonography for the judgement of parametrial invasion in regard of inflammatory stromal reaction

1993 ◽  
Vol 100 (7) ◽  
pp. 696-697 ◽  
Author(s):  
Gerald Gitsch ◽  
Josef Deutinger ◽  
Alexander Reinthaller ◽  
Gerhard Breitenecker ◽  
Gerhard Bernaschek
Keyword(s):  
Cervical Cancer ◽  
Diagnostic Value ◽  
Stromal Reaction ◽  
Parametrial Invasion

Histologic Findings of Uterine Niches

2020 ◽  
Vol 154 (5) ◽  
pp. 645-655
Author(s):  
Georgia Karpathiou ◽  
Celine Chauleur ◽  
Maroa Dridi ◽  
Pauline Baillard ◽  
Thomas Corsini ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cesarean Section ◽  
Prospective Studies ◽  
Treatment Modalities ◽  
Granulomatous Reaction ◽  
Stromal Reaction ◽  
Niche Formation ◽  
Uterine Scar ◽  
Fibroblastic Stroma ◽  
Epithelial Atypia

Abstract Objectives The disruption or defect of the myometrium in the uterine scar of a cesarean section (CS) has been known by various names, such as uterine niche, isthmocele, deficient uterine scar, scar pouch, or diverticulum. Symptomatology, risk factors for niche development, and available treatment modalities have been recently studied. However, the histologic features of this disease remain unknown. Methods The histologic features of eight uterine niches are thoroughly described and a summary of the most important aspects of the uterine niche literature is provided. Five cases of CS scars without niche formation are comparatively examined. Results Most uterine niches harbor endocervical mucosa, often cystically dilated and/or an atrophic or disorganized endometrial mucosa of lower uterine segment origin. Regenerative epithelial atypia and fibroblastic stromal reaction are frequent features. No granulomatous reaction, important inflammation, or hemorrhage is seen. CS scars without niche formation do not harbor endocervical mucosa or inclusion cysts, fibroblastic stroma, or regenerative atypia. Conclusions As more prospective studies of uterine niche development and treatment will be conducted, a detailed pathologic report with the criteria proposed herein can be designed.

Ruxolitinib-Induced Modulation of Bone Marrow Microenvironment in Patients with Myelofibrosis Is Associated with Inflammatory Cytokine Levels

Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 3182-3182 ◽  
Author(s):  
Hans Michael Kvasnicka ◽  
Juergen Thiele ◽  
Carlos E. Bueso-Ramos ◽  
William Sun ◽  
Jorge E. Cortes ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Research Funding ◽  
Janus Kinase ◽  
Apolipoprotein A1 ◽  
Term Therapy ◽  
Historical Cohort ◽  
Stromal Reaction ◽  
Fibrotic Process ◽  
Cytokine Levels

Abstract Background: The Janus kinase inhibitor ruxolitinib (RUX) has recently been shown to induce a meaningful reduction in bone marrow (BM) fibrosis in patients with intermediate-2 or high-risk myelofibrosis (MF) compared with best available therapy (BAT). The altered BM microenvironment in MF is generally associated with prominent pro-inflammatory changes and high levels of corresponding cytokines. We evaluated the complex BM stromal changes following up to 5 years of RUX therapy in a cohort of patients (pts) with primary, post-polycythemia vera, or post-essential thrombocythemia MF. Methods: BM biopsies were performed at protocol-defined intervals for RUX-treated pts at baseline (BL) and at 24 months (mo) (68 pts), 48 mo (38 pts), 54 mo (23 pts), 60 mo (10 pts), or 66 mo (4 pts). To compare the effects of long-term therapy on BM fibrosis we additionally included a historical cohort of pts with primary MF treated with BAT. Samples from the BAT cohort (192 pts) were matched with those from the RUX cohort according to BM morphology at BL. Analysis in the RUX cohort included immunohistochemical assessment of therapy-induced changes by applying specific antibodies (CD61 – megakaryocytes [MEG]; CD68 – macrophages [MAC]; MUM1 – plasma cells [PLC]). Changes in these parameters were determined by consensus after independent blinded review by 3 pathologists (HMK/JT/CBR). Results were categorized as improvement, stabilization, or worsening from BL. Changes in serum levels of 73 cytokines (BL vs 4 weeks) were available in 48 (of the 68; 71%) pts of the RUX cohort. Logarithmic transformation was applied to both BL and week 4 cytokine values, and a stepwise logistic regression method was implemented to identify significant predictors. A composite variable was constructed that reflects a linear combination of the most important predictors using the slope from the logistic analysis as the coefficients. ROC curves with the status of BM response as the dependent variable were generated and the area under the curve (AUC) was calculated as a measure of accuracy. Results: In line with previous results, the odds for improvement or stabilization of BM fibrosis were greater with RUX at all time points, whereas the odds of worsening were markedly reduced with RUX vs BAT. Improvement or stabilization of BM fibrosis with RUX was associated with concordant changes in both collagen deposition and osteosclerosis. As an indicator of therapy-induced reduction in the BM inflammatory stromal reaction, in more than 70% of pts a decrease in the amount of PLC was observed. In 48% of patients, RUX induced a reduction of MAC, while in 39% of cases their number remained unchanged. MEG frequency was reduced in 52% of cases post–RUX therapy, while an increase was observed in only 6.8% of samples. Furthermore, MEG atypia was reduced in 37% of cases, while in 55% of patients a stabilization effect of therapy was seen for this parameter. Multivariate regression identified 10 cytokines that strongly correlated with morphologic outcomes with different weighting factors for each of the predictive equations: CRP: C-reactive protein, IL-10: Interleukin 10, MDC: Macrophage- derived cytokine, SCF: Stem cell factor, TNFα: Tumor necrosis factor alpha, ApoA1: Apolipoprotein A1, EOT: Eotaxin, Hp: Haptoglobin, IgE: Immunoglobulin E, TIMP1: Tissue inhibitor of metalloproteinase-1. In all pts tested RUX induced a significant change of these identified cytokines by week 4. Individual changes in parameters of BM morphology were strongly associated with corresponding changes in cytokine levels. Decrease of BM fibrosis at 24 mo was strongly associated with reduced cytokine levels (AUC=0.85939, p=0.0134). Additionally, decreased frequencies of MEG, PLC, and MAC showed significant correlations with RUX-induced modulation of cytokines (MEG: AUC=0.942572, p=0.0176; PLC: AUC=0.838135, p=0.0331; MAC: AUC=0.965495, p=0.0033). Conclusions: These results demonstrate that long-term RUX therapy, unlike BAT, causes a marked modulation of the BM cellular microenvironment. The effect observed with RUX was seen across all aspects of the fibrotic process including the inflammatory BM stromal reaction associated with MF. The complex relationships between improvement of the BM microenvironment and RUX-dependent effects on inflammatory cytokines reinforce previous observations suggesting that sustained JAK inhibition may be disease-modifying in MF. Disclosures Kvasnicka: Novartis: Consultancy, Honoraria, Research Funding; Incyte Corporation: Consultancy, Honoraria. Thiele:AOP Orphan Pharmaceuticals: Consultancy, Honoraria; Incyte Corporation: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Research Funding; Novartis: Consultancy, Honoraria, Research Funding; Incyte Corporation: Consultancy, Honoraria; AOP Orphan Pharmaceuticals: Consultancy, Honoraria. Sun:Incyte Corporation: Employment. Verstovsek:Incyte Corporation: Research Funding.

scholarly journals Significance of Stromal Reaction Patterns in Invasive Urothelial Carcinoma

2005 ◽  
Vol 123 (6) ◽  
pp. 851-857 ◽  
Author(s):  
Hemamali Samaratunga ◽  
Peta Fairweather ◽  
David Purdie
Keyword(s):  
Urothelial Carcinoma ◽  
Stromal Reaction ◽  
Reaction Patterns
Sign in / Sign up

Export Citation Format

Share Document